SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS

摘要

A composition comprising an SL0101 [kaempferol 3-O-(3",4"-di-O-acetyl-a-L- rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.